Effect of clarithromycin on renal excretion of digoxin: Interaction with P-glycoprotein

Clinical Pharmacology and Therapeutics

Volumn 64, Issue 1, 1998, Pages 123-128

  Wakasugi, Hiroko ^b   Yano, Ikuko ^b   Ito, Tatsuya ^b   Hashida, Tohru ^b   Futami, Takahiro ^b   Nohara, Ryuji ^b   Sasayama, Shigetake ^b   Inui, Ken Ichi ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZULENE; BROMHEXINE; CEFOZOPRAN; CILASTATIN PLUS IMIPENEM; CLARITHROMYCIN; DIGOXIN; ENALAPRIL; FAMOTIDINE; FUROSEMIDE; GLYCERYL TRINITRATE; GLYCOPROTEIN P; ISOSORBIDE DINITRATE; LEVOFLOXACIN; MILRINONE; SARPOGRELATE; SPIRONOLACTONE; WARFARIN;

ADULT; ARTICLE; CASE REPORT; CELL LINE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIGOXIN BLOOD LEVEL; DRUG UPTAKE; FEVER; HEART ARRHYTHMIA; HEART DISEASE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; KIDNEY EPITHELIUM; MALE; ORAL DRUG ADMINISTRATION; PNEUMONIA; PRIORITY JOURNAL; TRANSCYTOSIS; URINARY EXCRETION;

ANTI-ARRHYTHMIA AGENTS; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; DIGOXIN; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; P-GLYCOPROTEIN;

EID: 0031845356     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90030-3     Document Type: Article

References (24)

1. Midoneck SR, Etingin OR. Clarithromycin-related toxic effects of digoxin [letter]. N Engl J Med 1995;333:1505.
2. Ford A, Smith LC, Baltch AL, Smith RP. Clarithromycin-induced digoxin toxicity in a patient with AIDS. Clin Infect Dis 1995;21:1051-2.
3. Brown BA, Wallace RJ Jr, Griffith DE, Warden R. Clarithromycin-associated digoxin toxicity in the elderly. Clin Infect Dis 1997;24:92-3.
4. Nawarskas JJ, McCarthy DM, Spinler SA. Digoxin toxicity secondary to clarithromycin therapy. Ann Pharmacother 1997;31:864-6.
5. Friedman HS, Bonventre MV. Erythromycin-induced digoxin toxicity [letter]. Chest 1982;82:202.
6. Maxwell DL, Gilmour-White SK, Hall MR. Digoxin toxicity due to interaction of digoxin with erythromycin. BMJ 1989;298:572.
7. Morton MR, Cooper JW. Erythromycin-induced digoxin toxicity. DICP 1989;23:668-70.
8. Lindenbaum J, Rund DG, Butler VP Jr, Tse-Eng D, Saha JR. Inactivation of digoxin by the gut flora: reversal by antibiotic therapy. N Engl J Med 1981;305:789-94.
9. Reuning RH, Geraets DR. Digoxin. In: Evans WE, Schentag JJ, Jusko WJ, editors. Applied pharmacokinetics. 2nd ed. Washington: Applied Therapeutics; 1986. p. 570-623.
10. 1). J Pharmacol Exp Ther 1992;263:840-5.
11. Schinkel AH, Wagenaar E, van Deemter L, Mol CAAM, Borst P. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 1995;96:1698-705.
12. Okamura N, Hirai M, Tanigawara Y, Tanaka K, Yasuhara M, Ueda K, et al. Digoxin-cyclosporin A interaction: modulation of the multidrug transporter P-glycoprotein in the kidney. J Pharmacol Exp Ther 1993;266:1614-9.
13. Hofsli E, Nissen-Meyer J. Reversal of drug resistance by erythromycin: erythromycin increases the accumulation of actinomycin D and doxorubicin in multidrug-resistant cells. Int J Cancer 1989;44:149-54.
14. 1 cells transfected with human MDR1 gene. Biochem Pharmacol 1997;53:741-6.
15. Suzuki M, Yoshida M. A new enzymatic serum creatinine measurement based on an endogenous creatinine-eliminating system. Clin Chim Acta 1984;143:147-55.
16. 1. J Pharmacol Exp Ther 1997;282:955-60.
17. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72: 248-54.
18. Hori R, Miyazaki K, Mizugaki M, Ogata H, Goto M, Ichimura F, et al. Estimation of population pharmacokinetic parameters in the Japanese; I: digoxin. Jpn J Ther Drug Monit 1994;11:7-17.
19. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987;84:7735-8.
20. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 1989;86:695-8.
21. Suwa T, Urano H, Kodama T, Nakamura M. Metabolic fate of TE-031 (A-56268) (VIII): absorption and excretion in humans (bioassay). Chemotherapy 1988;36:921-32.
22. 14C-TE-031 in rats, mice and dogs. Chemotherapy 1988;36(S-3):213-26.
23. Alderman CP, Allcroft PD. Digoxin-itraconazole interaction: possible mechanisms. Ann Pharmacother 1997;31: 438-40.
24. Gupta S, Kim J, Gollapudi S. Reversal of daunorubicin resistance in P388/ADR cells by itraconazole. J Clin Invest 1991;87:1467-9.